1. Cibis PA, Becker B, Okun E, et al. The use of liquid silicone in retinal detachment surgery. Arch Ophthalmol. 1962;68:590–599.
2. Moya R, Chandra A, Banerjee PJ, et al. The incidence of unexplained visual loss following removal of silicone oil. Eye. 2015;29:1477–1482.
3. Christensen UC, la Cour M. Visual loss after use of intraocular silicone oil associated with thinning of inner retinal layers. Acta Ophthalmol. 2012;90: 733–737.
4. Roca JA, Wu L, Berrocal M, et al. Un-explained visual loss following silicone oil removal: results of the Pan American Collaborative Retina Study (PACORES) Group. Int J Retina Vitreous. 2017; 3:26.
5. Lou B, Yuan Z, He L, et al. The changes of retinal saturation after long-term tamponade with silicone oil. Biomed Res Int. 2015;2015:713828.
6. Karimi S, Entezari M, Nikkhah H, et al. Effects of intravitreal silicone oil on subfoveal choroidal thickness. Ophthalmologica. 2018;239:159–166.
7. Kaneko H, Takayama K, Asami T, et al. Cytokine profiling in the sub-silicone oil fluid after vitrectomy surgeries for refractory retinal diseases. Sci Rep. 2017;7:2640.
8. Kaneko H, Matsuura T, Takayama K, et al. Increased retinal thinning after combination of internal limiting membrane peeling and silicone oil endotamponade in proliferative diabetic reti- nopathy. Ophthalmologica. 2017;238:226–235.
9. Sassa Y, Yoshida S, Ishikawa K, Asato R, Ishibashi T, Kono T. The kinetics of VEGF and MCP-1 in the second vitrectomy cases with proliferative diabetic retinopathy. Eye (Lond). 2016;30:746–753.
10. Zhao XY, Xia S, Chen YX. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. Antivascular endo- thelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised con- trolled trials. Br J Ophthalmol. 2018;102:1077– 1085.
11. Zaman Y, Rehman AU, Memon AF. Intravitreal avastin as an adjunct in patients with proliferative diabetic retinopathy undergoing pars plana vit- rectomy. Pak J Med Sci. 2013;29:590–592.
12. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127:688– 693.
13. Acan D, Karahan E, Kocak N, Kaynak S. Evaluation of systemic risk factors in different optical coherence tomographic patterns of dia- betic macular edema. Int J Ophthalmol. 2018;11: 1204–1209.
14. Bronson-Castain KW, Bearse MA Jr, Neuville J, et al. Adolescents with type 2 diabetes: Early indications of focal retinal neuropathy, retinal thinning and venular dilation. Retina. 2009;29: 618–626.
15. van Dijk HW, Verbraak FD, Kok PH, et al. Early neurodegeneration in the retina of type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2012; 53:2715–2719.
16. El Asrar AMA, Maimone D, Morse PH, Gregory S, Reder AT. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 1992;114:731–736.
17. Koskela U, Kuusisto S, Nissinen A, Savolainen M, Liinamaa M. High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy. Ophthalmic Res. 2013;49: 108–114.
18. Mao C, Yan H. Roles of elevated intravitreal IL- 1b and IL-10 levels in proliferative diabetic retinopathy. Indian J Ophthalmol. 2014;62:699.
19. Doganay S, Evereklioglu C, Er H, et al. Comparison of serum NO, TNF-a, IL-1b, sIL- 2R, IL-6, and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye. 2002;16:163.
20. Matsunaga N, Chikaraishi Y, Izuta H, et al. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology. 2008;115:1916–1922.
21. Witmer A, Vrensen G, Van Noorden C, Schlin- gemann R. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29.
22. Osaadon P, Fagan X, Lifshitz T, Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye. 2014;28:510.
23. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthal- mol. 2002;86:311–315.
24. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with prolif- erative diabetic retinopathy. Am J Ophthalmol. 2005;139:476–481.
25. Wang J, Chen S, Jiang F, et al. Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. PLoS One. 2014;9:e110531.
26. Sanchez RN, Chan CK, Garg S, et al. Interleu- kin-6 in retinal ischemia reperfusion injury in rats. Invest Ophthalmol Vis Sci. 2003;44:4006–4011.
27. Chong DY, Boehlke CS, Zheng Q-D, et al. Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci. 2008;49:3193–3200.
28. Ghasemi H, Ghazanfari T, Yaraee R, et al. Roles of IL-8 in ocular inflammations: a review. Ocul Immunol Inflamm. 2011;19:401–412.
29. Kowluru R, Odenbach S. Role of interleukin-1b in the pathogenesis of diabetic retinopathy. Br J Ophthalmol. 2004;88:1343–1347.
30. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450– 1452.
31. Zhang W, Liu H, Rojas M, Caldwell RW, Caldwell RB. Anti-inflammatory therapy for diabetic retinopathy. Immunotherapy. 2011;3: 609–628.
32. Yao Y, Li R, Du J, et al. Tumor necrosis factor-a and diabetic retinopathy: review and meta-anal- ysis. Clin Chim Acta. 2018;485:210–217.
33. Ru¨bsam A, Parikh S, Fort PE. Role of inflam- mation in diabetic retinopathy. Int J Mol Sci. 2018;19:942.
34. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343– 358.
35. Semeraro F, Cancarini A, Rezzola S, et al. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res. 2015;2015.
36. Wang W, Lo AC. Diabetic retinopathy: patho- physiology and treatments. Int J Mol Sci. 2018; 19.
37. Zandi S, Tappeiner C, Pfister IB, et al. Vitreal cytokine profile differences between eyes with epiretinal membranes or macular holes. Invest Ophthalmol Vis Sci. 2016;57:6320–6326.
38. Yamane K, Minamoto A, Yamashita H, et al. Proteome analysis of human vitreous proteins. Mol Cell Proteomics. 2003;2:1177–1187.
39. Steel D, Lotery A. Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treat- ment. Eye. 2013;27:S1–S21.
40. Harada T, Harada C, Kohsaka S, et al. Microg- lia-Mu¨ller glia cell interactions control neuro- trophic factor production during light-induced retinal degeneration. J Neurosci. 2002;22:9228– 9236.
41. Wahlin KJ, Campochiaro PA, Zack DJ, Adler R. Neurotrophic factors cause activation of intracel- lular signaling pathways in Mu¨ller cells and other cells of the inner retina, but not photoreceptors. Invest Ophthalmol Vis Sci. 2000;41:927–936.
42. Honjo M, Tanihara H, Kido N, Inatani M, Okazaki K, Honda Y. Expression of ciliary neurotrophic factor activated by retinal Mu¨ller cells in eyes with NMDA- and kainic acid- induced neuronal death. Invest Ophthalmol Vis Sci. 2000;41:552–560.
43. Takeuchi H, Inagaki S, Morozumi W, et al. VGF nerve growth factor inducible is involved in retinal ganglion cells death induced by optic nerve crush. Sci Rep. 2018;8:16443.
44. Fu S, Dong S, Zhu M, et al. Mu¨ller glia are a major cellular source of survival signals for retinal neurons in diabetes. Diabetes. 2015;64: 3554–3563.
45. Ichhpujani P, Jindal A, Jay Katz L. Silicone oil induced glaucoma: a review. Graefes Arch Clin Exp Ophthalmol. 2009;247(12):1585–1593.
46. Honavar SG, Goyal M, Majji AB, Sen PK, Naduvilath T, Dandona L. Glaucoma after pars plana vitrectomy and silicone oil injection for complicated retinal detachments. Ophthalmology. 1999;106:169–176; discussion 177.
47. Nguyen QH, Lloyd MA, Heuer DK, Baerveldt G, Minckler DS, Lean JS, Liggett PE. Incidence and management of glaucoma after intravitreal sili- cone oil injection for complicated retinal detach- ments. Ophthalmology. 1992;99:1520–526.
48. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axot- omy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774–786.
49. Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glauco- ma. Am J Ophthalmol. 1989;107:453–464.
50. Buckingham BP, Inman DM, Lambert W, et al. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci. 2008;28:2735–2744.
51. Scheerlinck LM, Kuiper JJ, Liem AT, et al. Electrolyte composition of retro-oil fluid and silicone oil-related visual loss. Acta Ophthalmol. 2016;94:449–453.
52. Winter M, Eberhardt W, Scholz C, Reichenbach A. Failure of potassium siphoning by Muller cells: a new hypothesis of perfluorocarbon liquid– induced retinopathy. Invest Ophthalmol Vis Sci. 2000;41:256–261.
53. Spiteri Cornish K, Lois N, Scott NW, et al. Vitrectomy with internal limiting membrane peeling versus no peeling for idiopathic full- thickness macular hole. Ophthalmology. 2014; 121:649–655.
54. Gregor ZJ. Surgery for idiopathic full-thickness macular holes. Eye (Lond). 1996;10:685–690.
55. Alberti M, la Cour M. Face-down positioning versus non-supine positioning in macular hole surgery. Br J Ophthalmol. 2015;99:236–239.